Cencora, Inc. Shows Potential, Yet Faces Competitive Headwinds
Cencora, Inc. COR appears well-positioned for growth thanks to its strong U.S. Healthcare Solutions segment and recent product launches. Nonetheless, it deals with intense competition in the pharmaceutical market.
The company’s shares, classified with a Zacks Rank of #3 (Hold), have increased by 13% year to date, outpacing the industry, which rose by 6.6%. In contrast, the S&P 500 Index has increased substantially, appreciating 28.6% during the same period.
Cencora stands among the world’s largest pharmaceutical service firms, focusing on drug distribution and services aimed at lowering healthcare costs and enhancing patient outcomes. Its current market capitalization is $44.82 billion.
Image Source: Zacks Investment Research
Over the next five years, Cencora’s bottom line is projected to increase by 10.6%. The company’s earnings have surpassed estimates in each of the last four quarters, achieving an average surprise of 6.59%.
Key Growth Factors for Cencora
Cencora’s recently reported fourth-quarter fiscal 2024 results revealed earnings per share (EPS) of $3.34, which corresponds to a 17% rise year over year, alongside revenues of $79.05 billion, marking a 15% increase. The U.S. Healthcare Solutions segment was pivotal in this growth, leading in specialty products and GLP-1 medications. Revenues in international markets increased by 6%, supported by strong performances in Europe and Canada, although the International segment’s operating income faced a minor decline due to escalating technology costs.
For fiscal 2025, the adjusted EPS is projected to be between $14.80 and $15.10, depicting an 8-10% increase compared to the previous year. Revenue growth of 7-9% is also anticipated, with expectations for both the U.S. and International Healthcare Solutions segments to advance within that same range. Adjusted operating income is forecasted to grow by 5-6.5%.
Cencora has made strides by acquiring Retina Consultants of America, which will enhance its specialty capabilities beyond oncology. This acquisition complements its pharmaceutical strategy and bolsters its Management Services Organization portfolio, aligning the company with the expanding retina and ophthalmology market.
Moreover, the focus on specialty pharmaceuticals is a significant growth driver for Cencora. The rising demand for GLP-1 products and specialty distribution to healthcare providers impact revenue positively. Further investments in distribution infrastructure and technology enhance logistics, particularly in handling temperature-sensitive products, thereby improving compliance with regulatory standards. Efforts in automation and continuity in international markets strengthen Cencora’s resilience and scalability. Partnerships with Express Scripts and Walgreens augment distribution capabilities and align resources to better meet customer needs.
Challenges Facing Cencora
Despite these positive developments, Cencora operates in a highly competitive pharmaceutical distribution sector. The generic drug industry is witnessing consolidation among customers and manufacturers, alongside facing global competition and regulatory hurdles.
The increase in sales of low-margin GLP-1 products, coupled with declining revenues linked to COVID-19, pressures profit margins. Furthermore, evolving U.S. healthcare policies, particularly changes in Medicare Part B and D reimbursement, may adversely affect profitability. A recent $418 million goodwill impairment concerning PharmaLex highlights the challenges in outsourced pharma services amid market pressures.
Increased competition in specialty and biosimilar markets poses additional risks to market share and pricing strategies.
Cencora, Inc. Price Overview
Cencora, Inc. price | Cencora, Inc. Quote
Estimate Trends
Cencora has seen a positive trend in earnings estimates for fiscal 2024. Within the last 30 days, the Zacks Consensus Estimate rose from $14.88 to $14.93 per share.
For the first quarter of fiscal 2025, the revenue consensus stands at $78.02 billion, reflecting an 8% increase from the previous year. The earnings expectation is set at $3.50, indicating growth of 6.7% year over year.
Other Stocks to Watch
Investors may want to consider other well-rated stocks in the broader medical industry, including Masimo MASI, Accuray ARAY, and AxoGen AXGN.
Currently, Masimo holds a Zacks Rank of #1 (Strong Buy) and has an estimated growth rate of 11.8% for 2025. There’s more information about today’s #1 Zacks Rank stocks here.
MASI’s earnings have exceeded estimates in each of the last four quarters, boasting an average surprise of 17.10%. Its stock price has appreciated by 49.4% compared to the industry’s 6.7% growth this year.
Accuray, with a Zacks Rank of #2 (Buy), shows a remarkable estimated growth rate of 1200% for 2025. However, its earnings have missed estimates in three of the past four quarters, yielding an average negative surprise of 141.97%.
Although ARAY’s shares have experienced a decline of 32.2%, the industry has witnessed a 6.7% increase year to date.
AxoGen also carries a Zacks Rank of 2 and is forecasted to achieve an impressive earnings growth rate of 252% for 2025, with a trailing four-quarter average surprise of 91.11%. AXGN’s stock has surged by 111% this year, far surpassing sector performance.
Upcoming Energy Opportunities: 5 Clean Energy Stocks to Watch
Energy plays a crucial role in our economy, representing a multi-trillion dollar industry with leading global companies.
With advancements in technology, clean energy is on the rise, aimed at replacing fossil fuels. Investments in clean energy initiatives are rapidly increasing, spanning areas like solar power and hydrogen fuel cells, providing potential for significant growth.
Companies emerging in this sector could become valuable additions to investment portfolios.
Download Nuclear to Solar: 5 Stocks Powering the Future to see Zacks’ top picks free today.
Accuray Incorporated (ARAY) : Free Stock Analysis Report
Masimo Corporation (MASI) : Free Stock Analysis Report
Cencora, Inc. (COR) : Free Stock Analysis Report
AxoGen, Inc. (AXGN) : Free Stock Analysis Report
For the full article on Zacks.com, click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
